ARVANIL (cas 128007-31-8) and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells

Add time:08/26/2019    Source:sciencedirect.com

In this study we analysed the regulation of gene expression by ARVANIL (cas 128007-31-8) and anandamide in human peripheral blood mononuclear cells (PBMCs) to clarify their immunosuppressive properties. PBMCs were activated, leading to CD36 down regulation, that was normalized by arvanil and anandamide. We used microarray technology to identify a regulatory pattern associated with cell proliferation in the presence of both substances. CD3–CD28 stimulated PBMCs showed a pattern of up-regulated and down-regulated genes after treatment with these substances. We selected and analysed several genes chosen by their function in the regulation of cell proliferation. We showed a transcriptional control of the CD36 gene by arvanil and anandamide associated with an increased protein expression, thus suggesting a possible role of CD36 in anandamide and arvanil anti-inflammatory pattern.

We also recommend Trading Suppliers and Manufacturers of ARVANIL (cas 128007-31-8). Pls Click Website Link as below: cas 128007-31-8 suppliers

Prev:Short CommunicationARVANIL (cas 128007-31-8), a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease
Next:Effect of ARVANIL (cas 128007-31-8) (N-arachidonoyl-vanillyl-amine), a nonpungent anandamide–capsaicin hybrid, on ion currents in NG108-15 neuronal cells)